both remain in clinical development, and their specific combination does not exist as a registered investigational product
Moreover, in hepatocellular carcinoma (HCC), antiangiogenic tyrosine kinase inhibitors (TKIs) are effective therapeutic agents and the main therapeutic effect is to induce severe hypoxia in the tumor microenvironment (TME) through depletion of the vascular density of tumor
The research base is, in effect, the output of one laboratory and its collaborators over thirty years
other routes (e.g., NG tube) can be used
It is important to note that these recommendations are largely based on clinical experience and observational practice
[1] Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014